No Interactions Between Previously Associated 2-Hour Glucose Gene Variants and Physical Activity or BMI on 2-Hour Glucose Levels

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.2337/db11-0973

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11181022

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Gene–lifestyle interactions have been suggested to contribute to the development of type 2 diabetes. Glucose levels 2 h after a standard 75-g glucose challenge are used to diagnose diabetes and are associated with both genetic and lifestyle factors. However, whether these factors interact to determine 2-h glucose levels is unknown. We meta-analyzed single nucleotide polymorphism (SNP)–BMI and SNP × physical activity (PA) interaction regression models for five SNPs previously associated with 2-h glucose levels from up to 22 studies comprising 54,884 individuals without diabetes. PA levels were dichotomized, with individuals below the first quintile classified as inactive (20%) and the remainder as active (80%). BMI was considered a continuous trait.Inactive individuals had higher 2-h glucose levels than active individuals ($\beta = 0.22 \text{ mmol/L [95\% CI } 0.13–0.31, P = 1.65 \times 10^{-6}$). All SNPs were associated with 2-h glucose ($\beta = 0.06–0.12 \text{ mmol/alelle, } P \leq 1.53 \times 10^{-7}$), but no significant interactions were found with PA ($P > 0.18$) or BMI ($P \geq 0.04$). In this large study of gene–lifestyle interaction, we observed no interactions between genetic and lifestyle factors, both of which were associated with 2-h glucose. It is perhaps unlikely that top loci from genome-wide association studies will exhibit strong subgroup-specific effects, and may not, therefore, make the best candidates for the study of interactions.

**Diabetes** 61:1291–1296, 2012
Glucose levels 2 h after a 75-g glucose challenge are used to diagnose diabetes and are associated with cardiovascular morbidity and mortality even below the diabetic threshold (1). A large number of type 2 diabetes–associated genetic variants have now been identified (2), and recent genome-wide meta-analyses identified five loci that were associated with postchallenge glucose at genome-wide levels of significance (3). Previously identified single nucleotide polymorphisms (SNPs) in TCF7L2 and GCKR were associated with 2-h glucose levels, as were newly identified loci in ADCY5, GIPR, and VPS13C. Risk alleles at each of these loci conferred 2-h glucose levels with effect sizes ranging from 0.07 to 0.11 mmol/L per allele (3), although with some heterogeneity.

Age, BMI, and physical inactivity are all associated with glycemia and are key risk factors for type 2 diabetes (4–6). Glucose levels at 2 h appear more susceptible to age- and lifestyle-mediated increases than fasting glucose levels. For example, physical activity (PA) levels have been shown to be inversely associated with 2-h glucose but not with fasting glucose (7,8). Differences in 2-h glucose between individuals at either end of the PA spectrum are appreciable, with the most active individuals having a mean 2-h glucose level ~1 mmol/L lower than those with low PA levels (7). Furthermore, lifestyle intervention trials including prescribed PA have been effective in decreasing the incidence of diabetes in individuals with impaired glucose tolerance at baseline (9)–(11). A risk allele at each of these loci confers a comparable risk for diabetes (11) and 2-h glucose elevation (11) and is therefore a good candidate for a lifestyle interaction. Therefore, we investigated the presence of gene–lifestyle interactions at these five 2-h glucose–associated loci (in or near GCKR, ADCY5, TCF7L2, VPS13C, and GIPR) by meta-analyzing SNP×PA and SNP×BMI interactions on 2-h glucose in up to 54,884 individuals from 22 studies.

RESEARCH DESIGN AND METHODS

Participating cohort characteristics. We meta-analyzed results from up to 22 Meta-Analyses of Glucose and Insulin Related Traits Consortium (MAGIC) studies (3) comprising up to 54,884 individuals. Study descriptors are detailed in Supplementary Table 1. Participants with known diabetes, those with fasting glucose ≥ 7 mmol/L, and individuals with a BMI < 18.5 kg/m² were excluded. All analyses were cross-sectional except for Atherosclerosis Risk in Communities Study (ARIC) where PA data were available at the visit –3 years before 2-h glucose measurement.

Lifestyle exposure classification. Study-specific details of the measurement of PA are in Supplementary Table 1. Where a quantitative measure of PA was available, individuals below the first quintile were classified as inactive and the remainder as active (i.e., ≥20 inactive and 80% active). In studies where PA data were categorical, the proportion of inactive individuals was dependent on the questionnaire used and reported in Supplementary Table 1. Inactive individuals were coded as 0 and active individuals as 1 in the analyses. BMI was treated as a continuous variable in the primary analyses.

Genotyping and statistical analysis. Genotyping methods are reported in Supplementary Table 1 and have been described in detail previously (3). Analyses from each study performed study-level analyses and submitted summary statistics to the meta-analysis group. We ran linear regression models testing the association of each SNP with 2-h glucose, adjusted for age, sex, fasting glucose, BMI, and PA (as a dichotomous variable), and any necessary study-specific variables. We also examined the association of each SNP with BMI, adjusted for

United Kingdom; the 46National Heart, Lung, and Blood Institute’s Framingham Heart Study, Boston, Massachusetts; the 47Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; the 48Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, California; the 49Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; the 50Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; the 51Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; 52Infection, Immunology, and Inflammation, University of Southampton, Southampton, United Kingdom; the 53Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts; the 54Folkhalsan Research Center, Helsinki, and Department of Social Services and Health Care, Jakobstad, Finland; the 55Diabetes and Endocrinology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden; the 56Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; the 57Interdisciplinary Center for Clinical Research, University of Leipzig, Leipzig, Germany; the 58University of Eastern Finland, Kuopio, Finland; the 59Harvard School of Public Health, Boston, Massachusetts; the 60General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts; the 61Department of Internal Medicine, CHUV, Lausanne, Switzerland; the 62Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; the 63Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; the 64Faculty of Medicine, University of Leipzig, Leipzig, Germany; the 65Department of Clinical Sciences, LiU, Linköping, Sweden; the 66Botnar Research Centre, University of Oxford, Oxford, United Kingdom; the 67Botnar Research Centre, University of Oxford, Oxford, United Kingdom; the 68Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, United Kingdom; the 69Institute of Cardiovascular Sciences, St George’s, University of London, London, United Kingdom; the 70Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom; the 71Department of Pediatrics, King’s College Hospital, London, United Kingdom; the 72Institute of Biomedical Sciences, University of Havana, Havana, Cuba; the 73National Institutes of Health, Bethesda, Maryland; the 74University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom; the 75Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts; the 76Broad Institute of MIT and Harvard, Cambridge, Massachusetts; and the 77Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts.

Corresponding author: Robert A. Scott, robert.scott@mrc-epid.cam.ac.uk.

Received 13 July 2011 and accepted 11 January 2012.

DOI: 10.2337/db11-0973

This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0973/-/DC1.

R.A.S. and A.Y. contributed equally to this work.

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
S

RESULTS

Study descriptives are reported in Supplementary Table 1. Individuals had a higher 2-h glucose (β = 0.22 mmol/L [95% CI 0.13–0.31], P = 1.63 × 10^{-6}) and BMI (β = 0.73 kg/m^2 [0.51–0.95], P = 1.42 × 10^{-10}) than active individuals. Higher BMI was also associated with higher 2-h glucose levels (β per 1 kg/m^2 = 0.086 mmol/L [0.08–0.10], P = 1.04 × 10^{-47}). SNP effects were consistent with those reported previously in overlapping studies (Fig. 1A) (3). However, we observed no significant interaction effects when analyses were limited to those studies showing association between PA and 2-h glucose (SNP×PA P ≥ 0.1 for interaction). Figure 1C shows the difference in SNP effect on 2-h glucose per 10 kg/m^2. Again, no statistically significant interaction effects were observed after correction for multiple testing (five tests for each hypothesis: α = 0.01), although rs1260326 in GCKR reached nominal levels of statistical significance (albeit with very small interaction effects). BMI-stratified results for rs1260326 showed that SNP effects were largest in the 30 to 34.9 kg/m^2 group (Supplementary Fig. 1), although few individuals at >35 kg/m^2 makes the smaller effect in this stratum difficult to interpret.

Association of SNPs with BMI. As can be seen from Fig. 2, TCF7L2 rs12243326 and GIPR rs10423928 were both associated with BMI. The alleles associated with increased 2-h glucose were associated with lower BMI. The TCF7L2 and GIPR SNPs were both associated with a 0.11 kg/m^2 lower BMI per allele (95% CI −0.17 to −0.04 and −0.20 to −0.03, respectively; Fig. 2). These findings were directionally consistent with those from previous meta-analyses by the GIANT consortium (13) (rs12243326 P = 5.7 × 10^{-4}; rs10423928 P = 1.9 × 10^{-4}).

DISCUSSION

Each of the gene variants investigated in the current study was robustly associated with 2-h glucose levels, as reported previously in overlapping studies (3). However, we observed

<table>
<thead>
<tr>
<th>Model</th>
<th>Gene</th>
<th>SNP</th>
<th>Effect allele</th>
<th>N</th>
<th>β (95% CI)</th>
<th>P</th>
<th>ρ^2</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>GCKR</td>
<td>rs1260326</td>
<td>T 45998</td>
<td>0.08 (0.06, 0.10)</td>
<td>9.20e-16</td>
<td>43.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ADCY5</td>
<td>rs2877716</td>
<td>C 46085</td>
<td>0.06 (0.04, 0.09)</td>
<td>1.53e-07</td>
<td>40.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TCF7L2</td>
<td>rs12243326</td>
<td>C 45650</td>
<td>0.08 (0.05, 0.10)</td>
<td>5.82e-11</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VPS13C</td>
<td>rs17271305</td>
<td>G 27913</td>
<td>0.08 (0.05, 0.11)</td>
<td>1.30e-08</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GIPR</td>
<td>rs10423928</td>
<td>A 28700</td>
<td>0.12 (0.09, 0.15)</td>
<td>6.02e-14</td>
<td>69.4</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>GCKR</td>
<td>rs1260326</td>
<td>T 48705</td>
<td>-0.03 (-0.08, 0.01)</td>
<td>0.18</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ADCY5</td>
<td>rs2877716</td>
<td>C 48792</td>
<td>-0.01 (-0.06, 0.05)</td>
<td>0.81</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TCF7L2</td>
<td>rs12243326</td>
<td>C 48362</td>
<td>0.01 (-0.04, 0.06)</td>
<td>0.39</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VPS13C</td>
<td>rs17271305</td>
<td>G 30620</td>
<td>0.02 (-0.06, 0.10)</td>
<td>0.65</td>
<td>18.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GIPR</td>
<td>rs10423928</td>
<td>A 32008</td>
<td>0.05 (-0.03, 0.13)</td>
<td>0.18</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>GCKR</td>
<td>rs1260326</td>
<td>T 53986</td>
<td>0.04 (0.00, 0.08)</td>
<td>0.04</td>
<td>24.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ADCY5</td>
<td>rs2877716</td>
<td>C 54450</td>
<td>-0.03 (-0.07, 0.02)</td>
<td>0.22</td>
<td>24.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TCF7L2</td>
<td>rs12243326</td>
<td>C 53517</td>
<td>-0.01 (-0.04, 0.03)</td>
<td>0.74</td>
<td>18.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VPS13C</td>
<td>rs17271305</td>
<td>G 32828</td>
<td>0.03 (-0.02, 0.07)</td>
<td>0.27</td>
<td>17.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GIPR</td>
<td>rs10423928</td>
<td>A 36498</td>
<td>0.06 (-0.02, 0.13)</td>
<td>0.13</td>
<td>31.8</td>
<td></td>
</tr>
</tbody>
</table>

**FIG. 1. A:** Effect of SNP is shown on 2-h glucose. The β-coefficient is the magnitude of the observed association. **B:** Shows the SNP×PA interaction effect in which the β-coefficient is the difference in SNP association effect between inactive and active individuals. Inactive individuals were coded as 0 and active individuals as 1; therefore, a value of 0 for the interaction coefficient reflects equivalent SNP effect in inactive and active strata, whereas a positive value reflects a larger SNP effect in active individuals. **C:** The SNP×BMI interaction is shown. Here, the β-coefficient is the difference in SNP effect per 10 kg/m^2 difference in BMI. A positive value reflects a larger SNP effect in those with higher BMI. The 2-h glucose-raising allele in A is always the effect allele.
no difference in effect of the gene variants studied among PA groups or with increasing BMI.

Previous studies have reported gene–lifestyle interactions, although often based on small sample sizes without independent replication (11). In light of the small effect sizes of most complex disease-associated SNPs, large sample sizes are important to investigate interactions (14). However, despite the large sample size in the current study, no significant interactions were observed between 2-h glucose-associated SNPs and established lifestyle correlates. Notably, however, in 6 of the 10 interaction meta-analyses we performed (i.e., 5 SNPs and interaction with PA or BMI), at least 1 individual study would have shown a significant interaction had it been studied in isolation. However, had we considered studies individually, for 200 tests of interaction we would have observed only nine interactions at $P < 0.05$, spread among a range of studies. We suggest that these associations reflect type I errors. Such a finding further supports our use of large sample sizes or independent replication to reduce the potential for type I error.

Although the variety of subjective measures and dichotomous classification of PA is an important limitation of the current study, inactive individuals had a higher 2-h glucose and a higher BMI than active individuals, suggesting the validity of our PA classification. Another factor may contribute to the absence of interactions: the SNPs we selected arose as top SNPs associated with 2-h glucose levels from a genome-wide meta-analysis (3). Although heterogeneity of associations was observed for ADCY5, TCF7L2, and GIPR (3), these SNPs had the strongest association $P$ values in the genome by virtue of their effect size relative to the variation in effect size among samples. One may not, therefore, expect significant variation in genetic effect between subgroups of the population. A similar approach to ours was recently used to investigate interactions between breast cancer-associated genes and risk-altering lifestyle exposures and also failed to detect significant interactions between them (15), although there was a suggestion that a physically active lifestyle attenuated genetic predisposition to obesity (16).

Although it has been suggested that the search for interactions should be informed by biologic plausibility (11), experience from the study of genetic main effects, where hypothesis-generating discovery approaches revolutionized the field (2), suggests that such an approach, not limited to those SNPs with extremely significant main effects, may be valuable in detecting gene–lifestyle interactions. Such approaches have been proposed and efforts are underway, but whether current analytic methods will yield success in the genome-wide search for gene–lifestyle interactions remains unclear.

Data from large-scale trials, such as the Finnish Diabetes Prevention Study (DPS) and Diabetes Prevention Program (DPP), have shown suggestions of differential response to intervention by genotype (17–22), although not always reaching statistical significance for interaction (17–19). However, lifestyle interventions in such studies often contain numerous lifestyle modifications, making interpretation of any interaction difficult, whereas large-scale genotype-stratified lifestyle intervention trials are not feasible. Therefore, prospective nested approaches will likely offer the most efficient approach for the study of gene–lifestyle interaction (23), allowing standardized measures of lifestyle at baseline and also the opportunity to study large numbers of individuals. Refined and standardized lifestyle exposure measurement will also represent a valuable alternative to straightforward increases in sample size (24).

Variants in TCF7L2 have previously been associated with diabetes (2,17) and a number of related traits (3,25). The diabetogenic, glucose-raising allele was previously associated with lower BMI, although not conclusively (26), and principally in individuals with diabetes (27,28). Here, we replicate this association in a larger sample size of participants without diabetes, where the glucose-raising allele at rs12243326 was associated with a 0.11 kg/m²-lower BMI (Fig. 2). Similarly, we report that the glucose-raising allele at variant TCF7L2 have previously been associated with diabetes (2,17) and a number of related traits (3,25). The diabetogenic, glucose-raising allele was previously associated with lower BMI, although not conclusively (26), and principally in individuals with diabetes (27,28). Here, we replicate this association in a larger sample size of participants without diabetes, where the glucose-raising allele at rs12243326 was associated with a 0.11 kg/m²-lower BMI (Fig. 2). Similarly, we report that the glucose-raising allele at
**GIPR** rs10423928 is associated with lower BMI (−0.11 kg/m² per allele). Lookup results from the GIANT consortium suggest that these associations are unlikely to arise from ascertainment bias.

Although the association with BMI highlights a genetic predisposition on BMI and the risk of confusing gene–gene and gene–environment interactions, the small proportion of variance in BMI explained by such SNPs is likely to limit the effect of this concern in our study. Because BMI is a major risk factor for diabetes and has a strong positive association with 2-h glucose, it seems counterintuitive that 2-h glucose-raising alleles at **TCF7L2** and **GIPR** are associated with lower BMI and highlights the etiologic complexity of type 2 diabetes.

In conclusion, in our study of up to 54,884 individuals from 22 studies, we found no evidence of gene–lifestyle interaction among the variants studied. This was despite the clear association of 2-h glucose with PA, BMI, and genetic exposures. Although the descriptive epidemiology of diabetes suggests an influence of gene–lifestyle interaction in its etiology, our study finds no evidence to that effect for SNPs known to be associated with 2-h glucose. Further, our study supports the use of large-scale analyses to robustly investigate gene–lifestyle interaction. In future, hypothesis-generating approaches may offer a valuable opportunity to detect gene–lifestyle interactions in type 2 diabetes and related traits.

**ACKNOWLEDGMENTS**

A complete list of disclosures and acknowledgments is included in the Supplementary Data online.

I.B. owns stock in GlaxoSmithKline and Incyte. No other potential conflicts of interest relevant to this article were reported.

R.A.S., A.Y.C., N.G., A.K.M., M.-F.H., A.T., O.P., J.B.M., E.I., I.B., J.C.F., P.W.F., J.D., N.J.W., and C.La. wrote the manuscript. R.A.S. and A.Y.C. were involved in management of the project and/or involved studies and in the project design and performed statistical analyses. N.G., A.K.M., M.F.-H., D.S., A.Y., D.B., Z.K., D.M., L.J.R.-T., H.M.S., V.La., S.G., and T.M.T. performed statistical analyses. N.B.-N., C.L.-M., and K.R. were involved in management of the project and/or involved studies and in genotyping and performed statistical analyses. N.L.G., A.U.J., and I.P. were involved in genotyping and performed statistical analyses. T.T., S.Be., S.R.B., S.Br., N.F.D., U.E., R.J.F.L., J.S.P., D.S.S., E.I., R.M.W., O.P., J.C.F., and C.La. were involved in management of the project and/or involved studies and in the project design. E.Bo., G.M., M.O.G., and C.H.S. contributed to data collection and phenotyping, were involved in genotyping, and performed statistical analyses. L.L.B., S.J.B., H.C., M.R.E., A.J., P.K., G.L., M.A.M., A.R.W., and W.X. were involved in genotyping. A.T., M.A., O.D.C., J.S.E., J.G., F.B.H., P.M.-V., F.P., and A.S. contributed to data collection and phenotyping. P.S.C. and M.S. contributed to data collection and phenotyping and were involved in genotyping. D.E.A., E.Br., Y.D.I.C., P.S.C., D.J.C., N.G.F., T.H., A.H., T.J., C.Le., V.Ly., M.M., K.E.N., F.R., D.R., P.S., G.W., D.R.W., M.B., and M.W. were involved in management of the project and/or involved studies. E.M.D., P.F., L.G., W.H.L.K., I.B., and P.W.F. were involved in management of the project and/or involved studies and in the project design, contributed to data collection and phenotyping, and were involved in genotyping. C.S.F., G.H., I.J., P.E.H.S., G.H.W., J.W.H., K.A.J., A.A.S., C.C., B.M.P., J.I.R., L.F., and P.V. were involved in management of the project and/or involved studies and in data collection and phenotyping. B.I., M.K.I., J.K., M.L., and J.B.M. were involved in management of the project and/or involved studies and in the project design, data collection, and phenotyping. M.Ku. was involved in management of the project and/or involved studies, in project design, and in genotyping, and performed statistical analyses. N.J.W. was involved in management of the project and/or involved studies, in project design, and in data collection and phenotyping. R.A.S. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**REFERENCES**


14. Smith PG, Day NE. The design of case-control studies: the in

polymorphism on progression to diabetes and response to troglitazone.
J Clin Endocrinol Metab 2007;92:1502–1509
Research Group. The Pro12Ala variant at the peroxisome proliferator-
activated receptor gamma gene and change in obesity-related traits in
the Diabetes Prevention Program. Diabetologia 2007;50:2451–2460
Study Group. Interaction of single nucleotide polymorphisms in ADRB2,
ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the
risk of type 2 diabetes mellitus and changes in characteristics of the metabolic
Study. The G-250A promoter polymorphism of the hepatic lipase gene
predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004;89:2019–2023
23. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the
24. Wong MY, Day NE, Luan JA, Chan KP, Wareham NJ. The detection of gene-
environment interaction for continuous traits: should we deal with measure-
ment error by bigger studies or better measurement? Int J Epidemiol
2003;32:51–57
GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of
26. Stolerman ES, Manning AK, McAteer JB, et al. TCF7L2 variants are asso-
ciated with increased proinsulin/insulin ratios but not obesity traits in the
variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest
2007;117:2155–2163
gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007;39:
218–225